We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

BD Diagnostics Acquires Kiestra and Expands Microbiology Portfolio

By LabMedica International staff writers
Posted on 13 Mar 2012
Print article
BD Diagnostics (Franklin Lakes, NJ, USA) has acquired Kiestra (Drachtan, the Netherlands), expanding the company microbiology portfolio to include new automated instrumentation technologies, which will enable it to offer total lab automation solutions to hospitals and laboratories worldwide.

Kiestra Lab Automation BV, which designs, develops, manufactures, markets, and sells lab automation solutions for the microbiology lab, complements BD’s microbiology portfolio of instruments, reagents, and supplies. Kiestra offers two lines of automated solutions: Total Lab Automation (TLA) and Work Cell Automation (WCA). Total Lab Automation is designed to significantly increase overall microbiology lab productivity, streamline workflow, and shorten the time to results. Kiestra’s Work Cell solutions will offer customers a modular and scalable approach to automate their lab within current space and budget constraints.

“We look forward to joining the BD team to expand automation across the entire microbiology and infectious disease testing process,” said Jetze Botma, vice president, microbiology laboratory automation, who served until the acquisition as CEO, KIESTRA Lab Automation. “Together with BD, we now have the opportunity to integrate automation across microbiology informatics, instruments, and consumables for maximum workflow efficiency, and have access to the global arena.”

Kiestra Lab Automation BV, which designs, develops, manufactures, markets, and sells lab automation solutions for the microbiology lab, complements BD’s microbiology portfolio of instruments, reagents, and supplies. Kiestra offers two lines of automated solutions: Total Lab Automation (TLA) and Work Cell Automation (WCA). Total Lab Automation is designed to significantly increase overall microbiology lab productivity, streamline workflow, and shorten the time to results. Kiestra’s Work Cell solutions will offer customers a modular and scalable approach to automate their lab within current space and budget constraints.

“We look forward to joining the BD team to expand automation across the entire microbiology and infectious disease testing process,” said Jetze Botma, vice president, microbiology laboratory automation, who served until the acquisition as CEO, KIESTRA Lab Automation. “Together with BD, we now have the opportunity to integrate automation across microbiology informatics, instruments, and consumables for maximum workflow efficiency, and have access to the global arena.”

BD is a global medical technology company that develops, manufactures, and sells medical devices, instrument systems, and reagents. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery, and production of new drugs and vaccines.

Related Links:

BD Diagnostics
Kiestra


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Aspergillus Test
REALQUALITY Aspergillus
New
Immunofluorescence Analyzer
MPQuanti

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Sekisui Diagnostics UK Ltd.